CA

Cardiogeni Plc

Developing engineered cellular medicines for regenerative treatment of heart failure.

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):
GB00BTBLFC12
LEI:
9845000F8F59ATZD8F92
Country:
United Kingdom
Address:
Celixir House Stratford-Upon-Avon Business & Technology Park, CV37 7GZ Stratford-Upon-Avon
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Cardiogeni Plc is a clinical-stage biotechnology company, founded by Nobel Laureate Professor Sir Martin Evans, that focuses on developing next-generation treatments for heart failure. The company specializes in regenerative medicine, utilizing a proprietary platform technology to create engineered cellular medicines. These therapies are designed to treat patients with heart failure, particularly those undergoing coronary artery bypass surgery. Cardiogeni's lead product candidate is CLXR-001. The company's mission is to become a market leader in heart failure regeneration by developing a new class of life-saving treatments.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 18:51
Annual Report
Annual Results to 31 March 2025
English 129.7 KB
2025-07-24 17:45
Share Issue/Capital Change
Details of Advanced Subscription & Company Update
English 21.0 KB
2025-07-24 08:00
Capital/Financing Update
£150,000 Advanced Subscription Agreement
English 14.2 KB
2025-07-02 08:00
Regulatory News Service
Appointment of corporate broker
English 11.6 KB

Automate Your Workflow. Get a real-time feed of all Cardiogeni Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cardiogeni Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fluicell AB Logo
Developing bioprinted tissues for regenerative medicine and advanced drug screening.
Sweden FLUI
FluoGuide A/S Logo
Develops fluorescent drugs to guide surgeons for more precise cancer removal and patient outcomes.
Denmark FLUO
FUSION ANTIBODIES PLC Logo
A CRO providing end-to-end antibody engineering services for therapeutic & diagnostic development.
United Kingdom FAB
FUTURA MEDICAL PLC Logo
Develops topical sexual health gels, including a fast-acting, over-the-counter ED treatment.
United Kingdom FUM
GENINCODE PLC Logo
AI-powered genetic tests for physicians, predicting and preventing cardiovascular disease.
United Kingdom GENI
Genomic Vision Logo
Develops DNA analysis tools using Molecular Combing for genetic research and diagnostics.
France GV
Genxone Spolka Akcyjna Logo
A biotech firm offering nanopore DNA/RNA sequencing services and medical diagnostics.
Poland GX1
Hamlet BioPharma AB Logo
Developing selective therapies for cancer and infections like bladder cancer and UTIs.
Sweden HAMLET
Hipower Energy Spolka Akcyjna Logo
Develops hydrogen solutions, mobile refueling, and CO2-to-methanol tech for energy markets.
Poland HPE
Israel HRON

Talk to a Data Expert

Have a question? We'll get back to you promptly.